Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Preexisting Vaccinia Virus Immunity Decreases SIV-Specific Cellular Immunity but Does Not Diminish Humoral Immunity and Efficacy of a DNA/MVA Vaccine

Sunil Kannanganat, Pragati Nigam, Vijayakumar Velu, Patricia L. Earl, Lilin Lai, Lakshmi Chennareddi, Benton Lawson, Robert L. Wilson, David C. Montefiori, Pamela A. Kozlowski, Bernard Moss, Harriet L. Robinson and Rama Rao Amara
J Immunol December 15, 2010, 185 (12) 7262-7273; DOI: https://doi.org/10.4049/jimmunol.1000751
Sunil Kannanganat
*Department of Microbiology and Immunology, Vaccine Research Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pragati Nigam
*Department of Microbiology and Immunology, Vaccine Research Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vijayakumar Velu
*Department of Microbiology and Immunology, Vaccine Research Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia L. Earl
†Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lilin Lai
*Department of Microbiology and Immunology, Vaccine Research Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lakshmi Chennareddi
*Department of Microbiology and Immunology, Vaccine Research Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benton Lawson
*Department of Microbiology and Immunology, Vaccine Research Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert L. Wilson
‡Gene Therapy Program, Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C. Montefiori
§Laboratory for AIDS Vaccine Research and Development, Department of Surgery, Duke University Medical Center, Durham, NC 27710
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela A. Kozlowski
‡Gene Therapy Program, Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Moss
†Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harriet L. Robinson
*Department of Microbiology and Immunology, Vaccine Research Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rama Rao Amara
*Department of Microbiology and Immunology, Vaccine Research Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF
Loading

Abstract

The influence of preexisting immunity to viral vectors is a major issue for the development of viral-vectored vaccines. In this study, we investigate the effect of preexisting vaccinia virus immunity on the immunogenicity and efficacy of a DNA/modified vaccinia Ankara (MVA) SIV vaccine in rhesus macaques using a pathogenic intrarectal SIV251 challenge. Preexisting immunity decreased SIV-specific CD8 and CD4 T cell responses but preserved the SIV-specific humoral immunity. In addition, preexisting immunity did not diminish the control of an SIV challenge mediated by the DNA/MVA vaccine. The peak and set point viremia was 150- and 17-fold lower, respectively, in preimmune animals compared with those of control animals. The peak and set point viremia correlated directly with colorectal virus at 2 wk postchallenge suggesting that early control of virus replication at the site of viral challenge was critical for viral control. Factors that correlated with early colorectal viral control included 1) the presence of anti-SIV IgA in rectal secretions, 2) high-avidity binding Ab for the native form of Env, and 3) low magnitude of vaccine-elicited SIV-specific CD4 T cells displaying the CCR5 viral coreceptor. The frequency of SIV-specific CD8 T cells in blood and colorectal tissue at 2 wk postchallenge did not correlate with early colorectal viral control. These results suggest that preexisting vaccinia virus immunity may not limit the potential of recombinant MVA vaccines to elicit humoral immunity and highlight the importance of immunodeficiency virus vaccines achieving early control at the mucosal sites of challenge.

Footnotes

  • This work was supported by National Institute of Allergy and Infectious Diseases/National Institutes of HealthGrants R01 AI057029 and R01 AI071852 (to R.R.A.), Yerkes National Primate Research Center Base Grant P51 RR00165, Emory Centers for AIDS Research Grant P30 AI050409, and National Institutes of Health Grant R24 RR16038 (to David I. Watkins).

  • The online version of this article contains supplemental material.

  • Abbreviations used in this paper:

    Ad5
    adenovirus type 5
    C
    control
    DI
    Dryvax-immune
    DN
    Dryvax-naive
    GM
    geometric mean
    MVA
    modified vaccinia Ankara
    rs
    Spearman’s rank correlation
    SHIV
    simian HIV
    TCLA
    T cell line adapted
    VV
    vaccinia virus.

  • Received March 11, 2010.
  • Accepted October 13, 2010.
View Full Text
PreviousNext
Back to top

In this issue

The Journal of Immunology: 185 (12)
The Journal of Immunology
Vol. 185, Issue 12
15 Dec 2010
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preexisting Vaccinia Virus Immunity Decreases SIV-Specific Cellular Immunity but Does Not Diminish Humoral Immunity and Efficacy of a DNA/MVA Vaccine
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Preexisting Vaccinia Virus Immunity Decreases SIV-Specific Cellular Immunity but Does Not Diminish Humoral Immunity and Efficacy of a DNA/MVA Vaccine
Sunil Kannanganat, Pragati Nigam, Vijayakumar Velu, Patricia L. Earl, Lilin Lai, Lakshmi Chennareddi, Benton Lawson, Robert L. Wilson, David C. Montefiori, Pamela A. Kozlowski, Bernard Moss, Harriet L. Robinson, Rama Rao Amara
The Journal of Immunology December 15, 2010, 185 (12) 7262-7273; DOI: 10.4049/jimmunol.1000751

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Preexisting Vaccinia Virus Immunity Decreases SIV-Specific Cellular Immunity but Does Not Diminish Humoral Immunity and Efficacy of a DNA/MVA Vaccine
Sunil Kannanganat, Pragati Nigam, Vijayakumar Velu, Patricia L. Earl, Lilin Lai, Lakshmi Chennareddi, Benton Lawson, Robert L. Wilson, David C. Montefiori, Pamela A. Kozlowski, Bernard Moss, Harriet L. Robinson, Rama Rao Amara
The Journal of Immunology December 15, 2010, 185 (12) 7262-7273; DOI: 10.4049/jimmunol.1000751
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Innate Immunity Together with Duration of Antigen Persistence Regulate Effector T Cell Induction
  • Regulatory Roles of IL-2 and IL-4 in H4/Inducible Costimulator Expression on Activated CD4+ T Cells During Th Cell Development
  • Induction of CD4+ T Cell Apoptosis as a Consequence of Impaired Cytoskeletal Rearrangement in UVB-Irradiated Dendritic Cells
Show more CELLULAR IMMUNOLOGY AND IMMUNE REGULATION

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606